News

New Gates Foundation Grant Opportunity–Tuberculosis Biomarkers

The Bill & Melinda Gates Foundation is now accepting letters of inquiry for the new grant program Biomarkers for the Diagnosis of Tuberculosis.

This grant program is part of the Grand Challenges in Global Health initiative. With up to $12 million of funding, the program seeks to validate biomarkers for use in developing a low cost, simple to use test that can quickly and accurately diagnose tuberculosis in low-resource settings. The term biomarker is intended to include all types of markers that have potential utility for tuberculosis diagnosis and can include markers associated with either host or pathogen biology.

Details and application instructions are available at http://www.grandchallenges.org/biomarkers/eb

Letters of inquiry are being accepted online until March 31, 2011 10:00 am PT.

After a review of submitted letters of inquiry, the foundation will invite full grant proposals from selected applicants.

Please sign up at http://www.grandchallenges.org/about/Pages/StayUpdated.aspx?Source=ThankYou.aspx to receive future grant opportunity announcements.

Thank you for your commitment to solving the world’s greatest health challenges.

###

Bill & Melinda Gates Foundation

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people – especially those with the fewest resources – have access to the opportunities they need to succeed in school and life. Based in Seattle, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...